Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.76 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16119627 | 0.90 | EPHX1 (0.62) | EPHX1POLBKCNH2TDP1MEN1 | |
| SCHEMBL2344070 | 0.89 | POLB (0.61) | EPHX1POLBKCNH2TDP1MEN1 | |
| SCHEMBL8970981 | 0.86 | PTK2 (0.70) | MEN1KMT2AALDH1A1MAPTGAA | |
| SCHEMBL16119541 | 0.84 | EPHX1 (0.56) | EPHX1POLBKCNH2TDP1MEN1 | |
| SCHEMBL8296751 | 0.84 | EPHX1 (0.68) | EPHX1POLBKCNH2TDP1MEN1 | |
| SCHEMBL24506879 | 0.83 | EPHX1 (0.67) | EPHX1POLBKCNH2TDP1MEN1 | |
| SCHEMBL10393407 | 0.82 | ALDH1A1 (0.82) | POLBKCNH2TDP1MEN1KMT2A | |
| SCHEMBL16119707 | 0.81 | EPHX1 (0.62) | EPHX1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL6118209 | 0.81 | EPHX1 (0.78) | EPHX1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL11105097 | 0.81 | EPHX1 (0.66) | EPHX1TDP1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2536286-A1 | INHIBITORS AND METHODS OF INHIBITING BACTERIAL AND VIRAL PATHOGENS | Siga Technologies, Inc. (US) | 2012-12-26 | — | — | EP | claimed |
| WO-2011103375-A1 | INHIBITORS AND METHODS OF INHIBITING BACTERIAL AND VIRAL PATHOGENS | SIGA TECHNOLOGIES, INC. (US) | 2011-08-25 | — | — | WO | claimed |
| EP-3173414-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA Biosciences Inc. (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2188271-B1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA BIOSCIENCES INC (US) | 2017-01-11 | — | — | EP | disclosed |
| EP-2536719-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | Acea Biosciences, Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8252822-B2 | Heterocyclic compounds and uses as anticancer agents | ACEA BIOSCIENCES, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20110207751-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA Therapeutics, Inc. | 2011-08-25 | — | — | US | disclosed |
| WO-2011103509-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA BIOSCIENCES INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| EP-2188271-A2 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | Acea Biosciences, Inc. (US) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009023402-A2 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA BIOSCIENCES INC. (US) | 2009-02-19 | — | — | WO | disclosed |
| US-20090048271-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA Therapeutics, Inc. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048271-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | MKI67, CCNC, HCCS | EPHX1 1565/4885POLB 481/4885KCNH2 4025/4885 |
| US-20110207751-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | MKI67, CCNC, NUDC | EPHX1 2075/4885POLB 521/4885KCNH2 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.